Zehnatx
1 known investors
Zehna Therapeutics develops small molecule drugs that target specific gut microbial enzymes to treat chronic diseases, with a focus on inhibiting the TMAO pathway in chronic kidney disease patients. The company's lead approach prevents the conversion of dietary choline to trimethylamine N-oxide, a metabolite linked to cardiovascular and metabolic disease.
Biotech
Founders & leadership
CV
Camilla V. SimpsonChief Executive Officer
RM
Robert Matunas, PhDHead of CMC and Nonclinical Sciences
MB
Mike Bishop, PhDHead of Early Development and Medicinal Chemistry